Erenumab Recombinant Human Monoclonal Antibody
Catalog Number | Pack Size | List Price* | Quantity | |
---|---|---|---|---|
MA542108 | 100 µg | 487,00 | Add |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Endotoxin level < 0.01EU/µg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt. Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the CGRP receptor, which is believed to play a critical role in migraine .
Category | Antibody |
Supplier | ThermoFisher |
Application | EL, WB |
Regulatory Status | RUO |
Immunogen | Human CALCRL/CGRP-R |
Host | Hu |
Isotype | IgG2,l |
Crossreactivity | Chemical |
Clonality | Recombi |
Format | Liquid; PBS; pH 7.5, with no preservative |
Concentration | 0.87 mg/mL |
Working Dilution | ELISA (Assay-dependent), Western Blot (Assay-dependent) |
Purity | Protein A |
Conjugation | Unconjugated |
Storage Conditions | -20° C, Avoid Freeze/Thaw Cycles |
Disclaimer | Alternative CatNo: MA5-42108 |
Tech. Data Sheet | View datasheet |
Link To Supplier | https://www.thermofisher.com |
Material Safety Data Sheet | Download PDF |